NCT07117474

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects

Conditions

• Subjects With Mild Hypertension

Interventions

Type	Name	Description
DRUG	HRS-9563, placebo	A single subcutaneous injection of HRS-9563 injection or placebo was administered

Timeline

• Start date: 2024-12-24
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2025-08-12
• Last updated: 2025-08-12

Locations

1 site across 1 country: China